Evidence map›Paper›PMID 37717406›Full record

ArticleBiomaterials2023

Actuated tissue engineered muscle grafts restore functional mobility after volumetric muscle loss.

Erin Rousseau, Ritu Raman, Tigist Tamir, Angel Bu, Shriya Srinivasan, Naomi Lynch, Robert Langer, Forest M White, Michael J Cima

Abstract read
In one paragraph

Article in Biomaterials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Autonomous Implants.Advanced materials (Deerfield Beach, Fla.) · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Overexpression of enhanced yellow fluorescent protein fused with Channelrhodopsin-2 causes contractile dysfunction in skeletal muscle.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Erin RousseauKoch Institute for Integrative Cancer Research, MIT, 77 Massachusetts Ave., Cambridge, MA, 02139, USA.
Ritu RamanDepartment of Mechanical Engineering, MIT, 77 Massachusetts Ave., Cambridge, MA, 02139, USA. Electronic address: ritur@mit.edu.
Tigist TamirKoch Institute for Integrative Cancer Research, MIT, 77 Massachusetts Ave., Cambridge, MA, 02139, USA; Department of Biological Engineering, MIT, 77 Massachusetts Ave., Cambridge, MA, 02139, USA.
Angel BuDepartment of Mechanical Engineering, MIT, 77 Massachusetts Ave., Cambridge, MA, 02139, USA.
Shriya SrinivasanKoch Institute for Integrative Cancer Research, MIT, 77 Massachusetts Ave., Cambridge, MA, 02139, USA.
Naomi LynchDepartment of Mechanical Engineering, MIT, 77 Massachusetts Ave., Cambridge, MA, 02139, USA.
Robert LangerKoch Institute for Integrative Cancer Research, MIT, 77 Massachusetts Ave., Cambridge, MA, 02139, USA.
Forest M WhiteKoch Institute for Integrative Cancer Research, MIT, 77 Massachusetts Ave., Cambridge, MA, 02139, USA; Department of Biological Engineering, MIT, 77 Massachusetts Ave., Cambridge, MA, 02139, USA.
Michael J CimaKoch Institute for Integrative Cancer Research, MIT, 77 Massachusetts Ave., Cambridge, MA, 02139, USA.

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
A New Device for Electrical & Chemical Modulation of Pathological Neural ActivityR01EB016101 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CIMA, MICHAEL J, GRAYBIEL, ANN M · 2013 to 2017
$5.5M
Micro-invasive biochemical sampling of brain interstitial fluid for investigating neural pathologyR01EB027717 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CIMA, MICHAEL J, LANGER, ROBERT SAMUEL · 2020 to 2023
$2.5M
NCI NIH HHS P30 CA014051NIBIB NIH HHS R01 EB016101NIBIB NIH HHS R01 EB027717
6 · The paper itself

Abstract

Damage that affects large volumes of skeletal muscle tissue can severely impact health, mobility, and quality-of-life. Efforts to restore muscle function by implanting tissue engineered muscle grafts at the site of damage have demonstrated limited restoration of force production. Various forms of mechanical and biochemical stimulation have been shown to have a potentially beneficial impact on graft maturation, vascularization, and innervation. However, these approaches yield unpredictable and incomplete recovery of functional mobility. Here we show that targeted actuation of implanted grafts, via non-invasive transcutaneous light stimulation of optogenetic engineered muscle, restores motor function to levels similar to healthy mice 2 weeks post-injury. Furthermore, we conduct phosphoproteomic analysis of actuated engineered muscle in vivo and in vitro to show that repeated muscle contraction alters signaling pathways that play key roles in skeletal muscle contractility, adaptation to injury, neurite growth, neuromuscular synapse formation, angiogenesis, and cytoskeletal remodeling. Our study uncovers changes in phosphorylation of several proteins previously unreported in the context of muscle contraction, revealing promising mechanisms for leveraging actuated muscle grafts to restore mobility after volumetric muscle loss.

Indexed as

Muscular DiseasesTissue EngineeringAnimalsMiceMuscle ContractionMuscle, SkeletalProstheses and ImplantsNeuromuscularPhosphoproteomicsRegenerative medicineSkeletal muscleTissue engineeringVolumetric muscle loss

Identifiers

PMID37717406
PMCPMC11512195

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.